12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Stelara ustekinumab: Phase III data

Top-line data from the double-blind Phase III PSUMMIT II trial in 312 adults with active psoriatic arthritis showed that 45 and 90 mg subcutaneous Stelara each met the primary endpoint of improving ACR20 response rates at week 24 vs. placebo (43.7% and 43.8%, respectively, vs. 20.2%, p<0.001 for both). In a subset of patients previously treated with tumor necrosis factor (TNF) inhibitors, Stelara led to ACR20 response rates at week 24 of 36.7% in the low-dose arm and 34.5% in the high-dose dose arm vs. 14.5% for placebo (p=0.006 and p=0.011, respectively).

Additionally, Stelara met the secondary endpoint...

Read the full 482 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >